<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002341</url>
  </required_header>
  <id_info>
    <org_study_id>236C</org_study_id>
    <secondary_id>ITR-USA-107</secondary_id>
    <nct_id>NCT00002341</nct_id>
  </id_info>
  <brief_title>A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole</brief_title>
  <official_title>An Open-Label Extension Study of Maintenance Therapy in HIV-Positive Subjects With Fluconazole-Refractory Oropharyngeal Candidiasis Who Have Responded to Itraconazole Oral Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To provide maintenance treatment with itraconazole solution for patients who were clinical&#xD;
      responders in the ITR-USA-94 protocol, even if they subsequently relapsed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who responded to therapy on protocol FDA 236B receive maintenance with itraconazole&#xD;
      oral solution for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Candidiasis, Oral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Met criteria for clinical response on protocol FDA 236B with no residual visible&#xD;
             lesion of oropharyngeal candidiasis upon completion of that study OR had initial&#xD;
             response on protocol FDA 236B with subsequent relapse and retreatment with&#xD;
             itraconazole solution or other therapies.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Underlying clinical condition that would preclude completion of study or place subject&#xD;
             at significant risk.&#xD;
&#xD;
          -  Judged unreliable with respect to physician's directives.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  Terfenadine.&#xD;
&#xD;
          -  Astemizole.&#xD;
&#xD;
          -  Systemic antifungals.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Previously documented disseminated candidiasis.&#xD;
&#xD;
          -  Previous clinically significant adverse event during treatment with itraconazole oral&#xD;
             solution, unless clearly attributable to an intercurrent illness or condition.&#xD;
&#xD;
          -  History of significant hepatic abnormalities or clinical evidence of significant&#xD;
             hepatic disease within 2 months prior to study entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any investigational drug (other than itraconazole solution) within 1 month prior to&#xD;
             study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Buckley Braffman Stern Med Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moskovitz B, Wu J, Baruch A, Benken C. Long term safety and efficacy of itraconazole oral solution (IS) for treatment of fluconazole refractory oropharyngeal candidiasis (OC) in HIV-positive patients (pts). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:124 (abstract no 325)</citation>
  </reference>
  <reference>
    <citation>Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1413-7. doi: 10.1089/088922299309919.</citation>
    <PMID>10555103</PMID>
  </reference>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Itraconazole</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Candidiasis, Oral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

